Highest-materiality recent filing
Mesa Labs Q1 revenue +1.0%; AOI up 19.5%; net income down on FX
Total revenues $60.1M, up 1.0% YoY; core organic growth 0.4%, first positive quarter.
Mesa Labs Q4 revenue up 2.6% but net loss $4.1M; BPD revenue falls 29.9% on export controls
Q4 revenue $63.7M (+2.6% YoY); net loss $4.1M ($0.75 loss per share) vs prior year loss of $7.1M.
CEO Gary Owens to depart by April 13; remains non-executive through June 22
Owens steps down as President and CEO effective ~April 13, 2026; stays in non-executive role until June 22, 2026.
Mesa Labs appoints Siddhartha Kadia as CEO to succeed Gary Owens effective April 13, 2026
Gary Owens departs as President and CEO effective April 12, 2026; separation not due to any disagreement.
Mesa Labs Q3 revenue up 3.6% to $65.1M; net income surges 317% to $3.63M
Revenue $65.1M, +3.6% YoY; core organic growth 1.2%.
Mesa Labs 2Q26 revenue up 5%, net income down 27.8% on tariffs and China headwinds
Total revenues $60.7M, +5.0% YoY; core organic growth 3.7%.
Mesa Laboratories draws $97M under credit facility to repay convertible notes due August 2025
Drew $97M under existing Credit Agreement to settle $97.5M of 1.375% Convertible Senior Notes maturing August 2025; total outstanding under credit facility now $108M.
Mesa Laboratories Reports First Quarter Fiscal 2026 Results
Total revenues increased 2.4% to $59,543,000 for the quarter ended June 30, 2025.
Mesa Labs Q4 revenue up 5.5% but net loss widens to $7.1M
Total revenues $62.1M, up 5.5% YoY; core organic growth 6.3%.
Mesa Labs Q3 revenue up 17.5% to $62.8M; core organic growth 13.2%
Revenue $62.8M (+17.5% YoY); non-GAAP core organic revenue +13.2%.
Revenue $57.8M (+8.8% YoY); net income $3.4M ($0.63 diluted EPS) vs. prior year loss.
Mesa Labs Q1 revenue $58.2M (+14.9%), EPS $0.62; operating income up 940%
Revenue $58.2M (+14.9% YoY); net income $3.4M (+717%); diluted EPS $0.62.
Mesa Labs Q4 net loss of $254.6M on $274.5M impairment; core organic revenues down 3.5%
Q4 revenue $58.9M (+6% YoY); core organic revenue declined 3.5% due to headwinds in Clinical Genomics and Biopharma.
Amended credit agreement: $75M term loan + $125M revolver, matures April 2029, interest at SOFR + 1.5%-3.5%.
Mesa Labs expects $271M non-cash impairment charge for FY2024, impacting two divisions
Non-cash impairment of ~$271M for Clinical Genomics and Biopharmaceutical Development divisions in Q4 FY2024.
Mesa Labs Q3 revenue down 1.5%; operating loss of $67K; core organic revenue declines 9%
Revenue $53.5M, down 1.5% YoY; core organic revenue declined 9%.
Mesa Labs Q2 revenue down 9.5% to $53.2M, net loss of $1.23M
Operating income turned negative at $(60), down 101.5% vs prior year.
Mesa Labs completes acquisition of GKE for €85M; expects €19-20M revenue add
Acquired GKE sterilization indicators business, SAL GmbH, and agreed to buy GKE China for €85M total.
Mesa Labs dismisses Plante & Moran, appoints RSM as auditor; discloses two material weaknesses
Audit Committee dismissed Plante & Moran and engaged RSM US, LLP effective August 28, 2023.
Mesa Labs Q4 revenue down 5.6%, AOI down 21%; FY net income down 50% to $0.9M
Q4 revenues $55.6M, -5.6% YoY; net income $0.6M ($0.11 diluted EPS) vs net loss $1.8M prior year.
Mesa Labs Q3 revenue -1% to $54.3M; core organic growth 4.6%; net income up 122%
Revenues $54,287K, down 1% YoY; organic revenue decline 2.1% due to currency and other headwinds.
Mesa Labs loses key customer Sema4; orders to drop starting Q3 FY2023
Sema4 exiting reproductive health screening; will significantly reduce consumables orders starting Q3 FY2023.
Mesa Labs Q2 revenue up 64% but GAAP EPS down 65%; non-GAAP AOI up 55%
Revenue $58.7M (+64% YoY); organic growth 12% (18% constant currency). Net income $1.3M (-65%), diluted EPS $0.24.
Mesa Labs Q1: revenue up 44% but net loss of $1.4M; organic growth slows to 3%
GAAP diluted EPS loss of ($0.27) vs prior-year EPS of $0.38; net loss of ($1.438M) from $1.995M income.
Mesa Labs reports Q4 GAAP operating loss of $110k; adjusted op income ex-unusual items up 31%
GAAP operating loss of $110k vs income of $4.3M a year ago; net loss $1.78M (-$0.34 diluted EPS).
Mesa Laboratories SVP Greg DiNoia to depart June 30, 2022; severance and retention bonus disclosed.
Greg DiNoia, SVP of Commercial Operations, will leave Mesa Labs on June 30, 2022.
Mesa Labs enters $150M at-the-market equity offering agreement with Jefferies
Agreement allows sale of up to $150M in common stock through Jefferies as sales agent.
Mesa Labs Q3 revenue up 60% to $54.7M; GAAP operating loss $2.5M on Agena acquisition costs
Q3 revenue $54.7M (+60% YoY); organic revenue growth 12%.
Mesa Labs Q2 FY22 revenue $35.84M (+12%), net income up 39% to $3.72M
Revenue $35.84M (+12% YoY); operating income $4.20M (-6%); net income $3.72M (+39%); diluted EPS $0.70 vs $0.51.
Mesa Labs appoints Shiraz Ladiwala to board, grants CEO special PSUs
Shiraz Ladiwala appointed to Board, effective Oct 28, 2021; board expands from 7 to 8 members.
On June 11, 2026, the board of directors (the “Board”) of Mesa Laboratories, Inc. (“Mesa” or the “Company”) approved the appointment of Lyndsey Crennen as the Chief Accounting Officer of the Company, effective as of her entry into the Employment Agreement described below.
Effective January 5, 2024, the Board of Directors (“Board”) of Mesa Laboratories, Inc. (“Mesa ”), upon the recommendation of its Nominating and Governance Committee, voted to expand the size of the Board from six to seven members, and to appoint Mark Capone to fill the newly created seat.
On May 3, 2023, John B. Schmieder, member of the Board of Directors (the “Board”), current Chair of the Nominating and Governance Committee, and member of the Audit Committee, informed the Board of Mesa Laboratories, Inc. that he has decided not to stand for re-election at the 2023 annual meeting of shareholders.
Effective June 23, 2022, Mesa Laboratories, Inc’s (“Mesa Labs”) Board of Directors (“Board”), upon the recommendation of the Nominating and Governance Committee appointed Tony Tripeny to its Board.
Mesa Laboratories, Inc. (the “Company”) and Mr. Greg DiNoia, Senior Vice Persident of Commercial Operations, have agreed that Mr. DiNoia’s employment will be terminated and he will leave the company on June 30, 2022
Effective October 28, 2021, Mesa Laboratories, Inc’s (“Mesa”) Board of Directors (“Board”) increased the size of Mesa’s Board from seven to eight members and upon the recommendation of the Nominating and Governance Committee, appointed Shiraz Ladiwala to fill the newly-created vacancy.
On September 24, 2021, David M. Kelly informed Mesa Laboratories, Inc. (the “ Company ”) of his planned retirement from the Board of Directors of the Company, including the Compensation Committee, to be effective as of close of business on April 3, 2022.
Max materiality 0.85 · Median 0.65 · Most common event earnings